NTRA - Natera, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Natera, Inc.

201 Industrial Road
Suite 410
San Carlos, CA 94070
United States
650-249-9090
http://www.natera.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees975

Key Executives

NameTitlePayExercisedYear Born
Dr. Matthew RabinowitzCo-Founder & Exec. Chairman823.62kN/A1973
Mr. Steve ChapmanCEO, Pres & Director571.88kN/A1979
Mr. Michael BrophyChief Financial Officer528.98kN/A1980
Mr. Jonathan SheenaCo-Founder, Chief Technology Officer & DirectorN/AN/A1973
Mr. Robert A. SchuerenChief Operating OfficerN/AN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Corporate Governance

Natera, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.